| __timestamp | Eli Lilly and Company | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 4932500000 | 3243000 |
| Thursday, January 1, 2015 | 5037200000 | 2472000 |
| Friday, January 1, 2016 | 5654900000 | 2548000 |
| Sunday, January 1, 2017 | 6070200000 | 19623000 |
| Monday, January 1, 2018 | 4681700000 | 30421000 |
| Tuesday, January 1, 2019 | 4721200000 | 32793999 |
| Wednesday, January 1, 2020 | 5483300000 | 28304000 |
| Friday, January 1, 2021 | 7312800000 | 620000 |
| Saturday, January 1, 2022 | 6629800000 | 755000 |
| Sunday, January 1, 2023 | 7082200000 | 1322000 |
| Monday, January 1, 2024 | 8418299999 |
Unleashing the power of data
In the ever-evolving landscape of pharmaceuticals, understanding cost structures is crucial. Eli Lilly and Company, a stalwart in the industry, has seen its cost of revenue grow by approximately 44% from 2014 to 2023. This increase reflects strategic investments and scaling operations. In contrast, Viridian Therapeutics, Inc., a smaller player, experienced a volatile cost pattern, peaking in 2019 with a 1,000% increase compared to 2014, before stabilizing in recent years.
Eli Lilly's consistent growth underscores its robust market position, while Viridian's fluctuations highlight the challenges faced by emerging biotech firms. The data from 2021 to 2023 shows a significant reduction in Viridian's costs, suggesting a strategic pivot or operational efficiency improvements. This analysis offers a window into the financial dynamics shaping the pharmaceutical sector over the past decade.
Analyzing Cost of Revenue: Eli Lilly and Company and GSK plc
Cost Insights: Breaking Down Eli Lilly and Company and Pfizer Inc.'s Expenses
Cost of Revenue Comparison: Eli Lilly and Company vs Neurocrine Biosciences, Inc.
Cost of Revenue: Key Insights for Eli Lilly and Company and BeiGene, Ltd.
Eli Lilly and Company vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Eli Lilly and Company and Bausch Health Companies Inc.'s Expenses
Cost of Revenue: Key Insights for Regeneron Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Comparing Cost of Revenue Efficiency: Takeda Pharmaceutical Company Limited vs Viridian Therapeutics, Inc.
Cost of Revenue Comparison: Biogen Inc. vs Viridian Therapeutics, Inc.
Cost of Revenue Comparison: BeiGene, Ltd. vs Viridian Therapeutics, Inc.
Amneal Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Wave Life Sciences Ltd. and Viridian Therapeutics, Inc.